NCT00183937

Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer

Completed Phase 2 Last updated 14 May 2018

What this trial tests

Phase 2 trial testing PS 341 in Prostate Cancer in 15 participants. Completed in 11 June 2012.

Timeline

30 April 2005

Primary endpoint
23 October 2010

11 June 2012

Quick facts

Lead sponsor	University of Southern California
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	30 April 2005
Primary completion	23 October 2010
Estimated completion	11 June 2012
Sites	1 location across United States

Drugs / interventions tested

• PS 341 — full drug profile →
• Docetaxel (Docetaxel) — full drug profile →

Conditions studied

• Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

University of Southern California

Who can join

18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is for patients who have been treated with surgical removal of the testes or hormone therapy (Lupron or Zoladex) and whose prostate cancer has worsened despite this treatment.

PS 341 is a type of drug known as a "proteasome inhibitor." By inhibiting the "proteasome" in cancer cells, PS-341 alters the way those cells divide). We hope to learn whether this combination chemotherapy decreases cancer symptoms and tests (prostate specific antigen, also called PSA), and to determine how frequently serious side effects might occur with this treatment for this stage of prostate cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Inflammation and tumor progression: signaling pathways and targeted intervention.
   Zhao H, Wu L, Yan G, Chen Y, et al · · 2021 · cited 1932× · PMID 34248142 · DOI 10.1038/s41392-021-00658-5
2. The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.
   Tundo GR, Sbardella D, Santoro AM, Coletta A, et al · · 2020 · cited 78× · PMID 32442437 · DOI 10.1016/j.pharmthera.2020.107579
3. OncoLoop: A Network-Based Precision Cancer Medicine Framework.
   Vasciaveo A, Arriaga JM, de Almeida FN, Zou M, et al · · 2023 · cited 38× · PMID 36374194 · DOI 10.1158/2159-8290.cd-22-0342
4. Prostate Cancer Stem Cells: Biology and Treatment Implications.
   Koukourakis IM, Platoni K, Kouloulias V, Arelaki S, et al · · 2023 · cited 17× · PMID 37834336 · DOI 10.3390/ijms241914890
5. Anti-Cancer Stem-Cell-Targeted Therapies in Prostate Cancer.
   Gogola S, Rejzer M, Bahmad HF, Alloush F, et al · · 2023 · cited 14× · PMID 36900412 · DOI 10.3390/cancers15051621
6. Pharmaceutical Agents for Targeting Autophagy and Their Applications in Clinics.
   Kench U, Sologova S, Smolyarchuk E, Prassolov V, et al · · 2024 · cited 6× · PMID 39458996 · DOI 10.3390/ph17101355
7. Targeting proteostasis for cancer therapy: current advances, challenges, and future perspectives.
   Zhang C, Li J, Tang Q, Li L, et al · · 2025 · cited 4× · PMID 41121138 · DOI 10.1186/s12943-025-02472-x
8. Signalling pathways in a nutshell: from pathogenesis to therapeutical implications in prostate cancer.
   Goncharov AP, Dicusari Elissaiou C, Ben Aharon Farzalla E, Akhvlediani G, et al · · 2025 · cited 2× · PMID 40372974 · DOI 10.1080/07853890.2025.2474175